Clinical trialNCT01874054CompletedPhase 1/PHASE2Interventional

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

SponsorSeagen Inc.Enrollment55Hodgkin Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to assess safety and efficacy of brentuximab vedotin in combination with bendamustine in patients with relapsed or refractory Hodgkin lymphoma. It is an open-label, 2-stage study designed to determine the recommended dose level of bendamustine in combination with brentuximab vedotin. The study will assess the safety profile of the combination treatment and determine what proportion of patients achieve a complete remission.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Neil Josephson, MD
Seagen Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham
Birmingham, Alabama, United States
Pacific Hematology Oncology Associates
San Francisco, California, United States
Stanford Cancer Center
Stanford, California, United States
Oncology Institute of Hope & Innovation, the
Whittier, California, United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Mayo Clinic Minnesota
Rochester, Minnesota, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
Columbia University Medical Center
New York, New York, United States
Jewish Hospital, the
Cincinnati, Ohio, United States
Case Western Reserve University / University Hospitals Case Medical Center
Cleveland, Ohio, United States
Saint Francis Hospital / Bon Secours
Greenville, South Carolina, United States
Charles A. Sammons Cancer Center / Baylor University Medical Center
Dallas, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bendamustine →Brentuximab vedotin →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Jun 2013
Primary completion: 31 Dec 2015
Completion: 20 Feb 2018
Last update posted: 12 Feb 2019
Registered enrollment: 55
Registry id: NCT01874054

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.